In order to meet clinical needs, we adhere to a product strategy combining in-depth exploration in technical advantages with expansion in cutting-edge biotechnology. Our R&D works will focus on "recombinant proteins and microecological agents" in the near future, and then "antibody drugs" in the middle and later periods. Meanwhile, we will also accelerate the project reserve in cutting-edge biotechnology, such as cell therapy, gene therapy, gene vaccination and biological testing, and incubate innovative drugs-based new technology platforms.
Scan Code Consultation
